Intravacc's 20-year legacy in the design, development, and characterization of conjugate vaccines speaks volumes about our commitment to combating diseases with time-tested and cost-effective solutions.
Conjugate vaccines, hailed for their success in preventing bacterial infections, are engineered by covalently binding a bacterial polysaccharide or peptide—an agent that alone cannot induce immunological memory—to a protein carrier antigen. This fusion triggers a potent and sustained immunological response. We employ a range of carriers, including tetanus toxoid, diphtheria toxoid (CRM197), and Outer Membrane Vesicles (OMVs), to craft effective conjugate vaccines.
Intravacc has honed the art of polysaccharide isolation and optimization, tailoring their length to maximize efficacy. Our arsenal includes versatile conjugation methods suitable for synthetic sugar antigens and peptides.
Beyond production, we possess the proficiency to comprehensively characterize conjugate vaccines. We offer a suite of services to evaluate production processes and ensure vaccine quality. That suite includes fully defined vaccine batches that can meet the specific needs of both research and Good Manufacturing Practices (GMP) and advanced techniques for polysaccharide purification that ensure the purity of vaccine components. Our expertise extends to both USP and DSP (upstream and downstream processing). Coupled with analytical capabilities like HPLC (High-Performance Liquid Chromatography), MS (Mass Spectrometry), NMR (Nuclear Magnetic Resonance), and colorimetric assays, we can meticulously evaluate and optimize every stage of the vaccine production process.
Learn more about Con-Vacc.
Our unwavering dedication to science and innovation empowers our partners in the creation of conjugate vaccine solutions that combat bacterial infections effectively and reliably. For example, Intravacc's conjugate Hib vaccine has been saving lives in the Indian market for years. Our contributions to that development are substantiated by 6 published manuscripts and 1 patent family. More recently, we collaborated in a consortium to develop a semi-synthetic conjugate vaccine against Shigella flexnerii 2a. We led the process development and scale-up and subsequently produced the vaccine for phase I and II clinical studies. This vaccine is currently in phase II clinical trials.
See which of our vaccine candidates build on Con-Vacc.
Partner with us to advance your vaccine projects.